[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.
Read more 
Oncodesign can help you select the appropriate in vivo model for your research program
Since 1995, Oncodesign has been developing models to study and treat cancer. Our extensive knowledge covers a wide in vivo pharmacological scope from syngeneic to xenograft including humanized models.
If the perfect model is not available, we can develop a custom one with you.
Category
At Oncodesign
Location of tumor
Species information
More details
Syngeneic
Syngeneic models - at Oncodesign
Oncodesign has over 140 Models available in 5 Cancer (breast, lung, pancreas, liver, ovary).
Syngeneic models - location of tumor
Subcutaneous, systemic, orthotopic
Syngeneic models - species information
Rodent tumor, rodent stroma, rodent immune cells, rodent metabolism
Syngeneic models - more details
Syngeneic models – inbred mice or rat bearing an engrafted tumor derived from a genetically identical mouse strain – are invaluable preclinical research tools that enable tumor studies in the context of a complete and functional immune system.
These models are powerful tools for studying tumor-immune system interactions and testing innovative immune-oncology therapeutics preclinically especially, combination therapies.
Cell-line-derived xenograft (CDX)
CDX models - at Oncodesign
Oncodesign has established and characterized more than 400 CDX including cell line derived from PDX and covering both subcutaneous and orthotopic models as well as experimental metastasis models.
CDX models - location of tumor
Subcutaneous, systemic, orthotopic
CDX models - species information
Human tumor, rodent stroma, immunodeficient, rodent metabolism
CDX models - more details
CDX models are a research model for understanding the mechanism of action and the efficacy evaluation of anti-cancer therapies. The establishment of CDX models involves inoculation of tumor cells into immunodeficient mice or rat. Due to the long-term cell passage in vitro, CDX models have the characteristics of high homology, easy construction and reproducibility.
Patient-derived xenograft (PDX)
PDX models - at Oncodesign
Through collaborative partnerships with clinicians and scientific experts, Oncodesign is continually building a collection of well characterized, annotated PDX models.
PDX models - location of tumor
Subcutaneous, orthotopic
PDX models - species information
Human tumor, rodent stroma, immunodeficient, rodent metabolism
PDX models - more details
PDX – where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse – used to create an environment that allows for the natural growth of cancer, its monitoring and corresponding treatment evaluations for the original patient. They reflect the diversity and heterogeneity of tumors and the evidence they provide can be verified in the patient tissues from which they were derived originally. They are anticipated to efficiently bridge non-clinical and clinical data in translational research.
Humanized
Humanized models - at Oncodesign
Oncodesign has developed a broad range of humanized immune system (HIS) models used for in vivo evaluation of immunomodulatory agents with mice xenografted with either cancer cell lines or patient-derived tumors, taking care about many different parameters (mechanism of action of the test compound, host mice, tumor growth and genomic characteristics, immune cell profile…) to define a custom-made preclinical model.
Humanized models - location of tumor
Immuse systems (PBMCs or HCSs)
Humanized models - species information
Human tumor, mouse stroma, human immune cells, human metabolism
Humanized models - more details
The humanized mouse model is established by the transplantation of human-derived peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs) as well as specific human immune cells such as Dendritic Cells (DCs), T cells, subset of T cells (e.g. gdT cells) or NK cells in highly immunodeficient mice.
Effective immunity against cancer involves complex interaction between the tumor, the host and the environment. Investigation and assessment of novel cancer immunotherapy approaches require the use of appropriate preclinical animal models that sufficiently reflect the physiological situation in cancer patients and that must be chosen carefully to address a specific scientific question. each model supporting different types of studies.
In combination with our medicinal chemists, in vitro biologists and pharmacologists, our integrated team can expedite your research program. Learn more about our integrated services:
- INPACT: integrated service in preclinical pharmacology
- DRIVE-IDDS: integrated drug discovery solutions to generate novel drug candidates
Let’s explore our in vivo models in the following case studies
Disease efficacy models of cancer immunotherapy combined with radiotherapy in syngeneic mice
In this example, mice were subcutaneously (SC) injected with CT-26 murine colon tumor cells on day 0. Mice were randomized based on tumor volume on day 12 and treated with imaged guide 3D radiotherapy at 8Gy for three consecutive days. T/C % (day 21) indicates the efficacy of radiotherapy.
Moreover, combined-modality approaches with immunotherapy may increase the curative capacity of radiation therapy.
Oncodesign has developed several models for such combined-modality approaches (CT-26, 4T1, EMT6, B6-F10, RenCa, etc.).
Legend: Tumor localized radiotherapy on mice with CT-26 murine colon tumor cells.
PDX models: Single Mouse Preclinical Trial (SMPT) for in vivo profiling and drug combination optimization
In this SMPT study including 27 colon PDXs, tumor models were treated with standard of care (SoC) alone (5-FU or Oxaliplatin) and FOLFOX (5-FU, Oxaliplatin, folinic acid).
Legend: SMPT study including 27 colon PDXs
FOLFOX increased the tumor response when compared to each mono therapies (in colon PDX models). Combination therapy increased the tumor response when compared to each mono therapies (in colon PDX models)
Oncodesign is continually building a collection of well characterized models. We currently have more than 500 models covering 35 cancer pathologies.
Let’s talk about your project to see which model would best suit your research program.
Chi-Mice® case study – Immune checkpoint inhibitor in humanized model
NOG (NOD/Shi-scid/IL-2Rγnull) mice were injected intraperitonially (IP) with NIH:OVCAR-3 human ovarian adenocarcinoma cells. Mice were randomized on day 20 based on CA125 plasma level (i.e. the corresponding biomarker in this example). Human peripheral blood mononuclear cells cells (PBMCs) were injected intravenous (IV) on day 21. Intravenous treatment with pembrolizumab started on day 21 once a week at 10 mg/kg/injection. Tumor development was monitored once a week by measuring CA125 level in mouse blood using ELISA’s analytical assay.
Pembrolizumab treatment was efficient in reducing CA125 level compared to isotype control as observed at day 40.
Legend: Efficacy of a immune checkpoint inhibitor, measurement of circulating biomarker in NIH-OVCAR-3 ovarian carcinoma in PBMC-humanized NOG mouse model
To support your research efforts in oncology and immuno-oncology, our integrated and customized package INPACT PoC Oncology contains all the requirement for a successful preclinical program.